Press Release

View printer-friendly version Back

Lantheus Holdings, Inc. Reports 2017 Fourth Quarter and Full Year Financial Results; Provides 2018 Guidance

  • Company exceeds full year 2017 guidance, posts revenues of $331.4 million, net income of $123.4 million and Adjusted EBITDA of $94.1 million; full year 2017 worldwide revenues increase 9.8%; DEFINITY® worldwide revenues increase 19.5% over prior year
  • Posts fourth quarter 2017 worldwide revenues of $81.2 million, a 9.3% increase over prior year period; fourth quarter DEFINITY worldwide revenues increase 22.2%
  • Provides 2018 financial guidance, including revenues of $337 to $342 million and Adjusted EBITDA of $85 to $90 million

NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Feb. 26, 2018-- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, today reported financial results for its fourth quarter and full year ended December 31, 2017.

The Company’s worldwide revenues for the fourth quarter of 2017 totaled $81.2 million. This represents an increase of 9.3% compared to $74.4 million for the fourth quarter of 2016. For the full year 2017, worldwide revenues totaled $331.4 million, compared to $301.9 million in 2016. Excluding the impact of a $5.0 million up-front payment received in the second quarter of 2017 from GE Healthcare under the flurpiridaz F 18 collaboration and license agreement, full year 2017 revenue totaled $326.4 million, exceeding 2017 guidance of $323 million to $325 million. Full year revenue results were driven by 19.5% growth in worldwide sales of DEFINITY®, 5.5% growth in worldwide sales of TechneLite® and 7.9% growth in worldwide sales of Xenon.

Net income for the fourth quarter of 2017 totaled $97.1 million, or $2.47 per diluted share, compared to $4.9 million, or $0.13 per diluted share, for the fourth quarter of 2016. Full year 2017 net income totaled $123.4 million, compared to $26.8 million in 2016. The full year improvement is primarily attributable to the release of our valuation allowance against deferred tax assets, as well as DEFINITY and Xenon revenue growth and lower interest expense following the refinancing and subsequent repricing of our debt facility during 2017. This was partially offset by increased operating expenses for sales and marketing as well as costs related to strategic initiatives.

The Company’s fourth quarter 2017 Adjusted EBITDA (as outlined in the GAAP to non-GAAP reconciliation provided below) was $20.8 million, or 25.7% of revenues, compared to $19.8 million, or 26.7% of revenues, for the fourth quarter of 2016. Full year 2017 Adjusted EBITDA was $94.1 million, or 28.4% of revenues, compared to $78.3 million, or 25.9% of revenues, for 2016. Excluding the impact of a $5.0 million up-front payment received in the second quarter of 2017 from GE Healthcare under the flurpiridaz F 18 collaboration and license agreement, full year Adjusted EBITDA totaled $89.1 million, or 27.3% of revenues, exceeding 2017 guidance of $86 million to $88 million. Higher Adjusted EBITDA for full year 2017 was driven by DEFINITY and Xenon revenue growth, partially offset by sales and marketing expenses attributable to sales growth in DEFINITY as well as costs related to strategic initiatives.

“We are pleased to announce such a successful finish to 2017, a milestone year for the Company on many fronts,” commented Mary Anne Heino, President and CEO. “Our performance and improved balance sheet have positioned us well to make the requisite investments in our own internal initiatives as well as potential external opportunities to augment our strong core business and future growth.”

Outlook

The Company anticipates worldwide revenues for full year 2018 of approximately $337 million to $342 million, compared to $326.4 million in 2017 (which excludes the $5 million up-front payment received from GE Healthcare). For the first quarter of 2018, the Company expects worldwide revenues in the range of $78 million to $83 million.

The Company anticipates full year 2018 Adjusted EBITDA, as described in the GAAP to non-GAAP reconciliation provided later in this release, of $85 million to $90 million, representing 24.9% to 26.7% of anticipated worldwide revenues. For the first quarter of 2018, the Company expects Adjusted EBITDA in the range of $18 million to $21 million.

The Company’s guidance for worldwide revenues and Adjusted EBITDA are forward-looking statements. They are subject to various risks and uncertainties that could cause the Company’s actual results to differ materially from guidance. Forward-looking statements are not predictions of the Company’s actual performance. See the cautionary information about forward-looking statements in the “Safe-Harbor Statement” section of this press release.

Internet Posting of Information

The Company routinely posts information that may be important to investors in the “Investors” section of its website at www.lantheus.com. The Company encourages investors and potential investors to consult its website regularly for important information about the Company.

Conference Call and Webcast

As previously announced, the Company will host a conference call starting at 4:30 p.m. Eastern Time today. To access the live conference call via telephone, please dial 1-866-498-8390 (U.S. callers) or 1-678-509-7599 (international callers) and provide passcode 9165309. A live audio webcast of the call also will be available in the Investors section of the Company’s website at www.lantheus.com.

A replay of the audio webcast will be available in the Investors section of our website at www.lantheus.com approximately two hours after completion of the call and will be archived for 30 days.

The conference call will include a discussion of non-GAAP financial measures. Reference is made to the most directly comparable GAAP financial measures, the reconciliation of the differences between the two financial measures, and the other information included in this press release, our Form 8-K filed with the SEC today, or otherwise available in the Investor Relations section of our website located at www.lantheus.com.

The conference call may include forward-looking statements. See the cautionary information about forward-looking statements in the safe-harbor section of this press release.

About Lantheus Holdings, Inc. and Lantheus Medical Imaging, Inc.

Lantheus Holdings, Inc. is the parent company of LMI, a global leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products. LMI provides a broad portfolio of products, including the echocardiography contrast agent DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; TechneLite® (Technetium Tc99m Generator), a technetium-based generator that provides the essential medical isotope used in nuclear medicine procedures; and Xenon (Xenon Xe 133 Gas), an inhaled radiopharmaceutical imaging agent used to evaluate pulmonary function and for imaging the lungs. The Company is headquartered in North Billerica, Massachusetts with offices in Puerto Rico and Canada. For more information, visit www.lantheus.com.

Non-GAAP Financial Measures

The Company uses non-GAAP financial measures, such as revenues excluding the impact of foreign currency; adjusted operating income; adjusted net income and its line components; Adjusted EBITDA; adjusted net income per share - diluted; and free cash flow. The Company’s management believes that the presentation of these measures provides useful information to investors. These measures may assist investors in evaluating the Company’s operations, period over period. The measures may exclude such items which may be highly variable, difficult to predict and of a size that could have substantial impact on the Company’s reported results of operations for a period. Management uses these and other non-GAAP measures internally for evaluation of the performance of the business, including the allocation of resources and the evaluation of results relative to employee performance compensation targets. Investors should consider these non-GAAP measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.

Safe Harbor for Forward-Looking and Cautionary Statements

This press release contains “forward-looking statements” as defined under U.S. federal securities laws, including statements about our 2018 outlook. Forward-looking statements may be identified by their use of terms such as anticipate, believe, confident, could, estimate, expect, intend, may, plan, predict, project, target, will and other similar terms. Such forward-looking statements are subject to risks and uncertainties that could cause actual results to materially differ from those described in the forward- looking statements. Readers are cautioned not to place undue reliance on the forward-looking statements contained herein, which speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law. Risks and uncertainties that could cause our actual results to materially differ from those described in the forward-looking statements are discussed in our filings with the Securities and Exchange Commission (including those described in the Risk Factors section in our Annual Reports on Form 10-K and our Quarterly Reports on Form 10-Q). This press release includes forward-looking non-GAAP guidance for 2018 Adjusted EBITDA. No reconciliation of this forward-looking non-GAAP guidance was included in this press release because, due to the high variability and difficulty in making accurate forecasts and projections of some of the excluded information and the fact that some of the excluded information is not readily ascertainable or accessible, the Company is unable to quantify certain amounts that would be required to be included in the most directly comparable GAAP financial measure without unreasonable efforts.

– Tables Follow –

 

Lantheus Holdings, Inc.

Consolidated Statements of Operations

(in thousands, except per share data – unaudited)

 

 

  Three Months Ended
December 31,
  Year Ended
December 31,
2017   2016 2017   2016
Revenues $ 81,241 $ 74,350 $ 331,378 $ 301,853
Cost of goods sold 43,342   39,703   169,243   164,073  
Gross profit 37,899   34,647   162,135   137,780  
Operating expenses
Sales and marketing 10,423 8,686 42,315 36,542
General and administrative 14,293 9,990 49,842 38,832
Research and development 3,976   3,710   18,125   12,203  
Total operating expenses 28,692 22,386 110,282 87,577
Gain (loss) on sales of assets   (120 )   6,385  
Operating income 9,207 12,141 51,853 56,588
Interest expense 4,263 5,819 18,410 26,618
Debt retirement costs 481 1,896
Loss on extinguishment of debt 281 2,442
Other (income) expense (6,601 ) 97   (8,638 ) (220 )
Income before income taxes 11,264 5,744 39,639 28,294
Income tax (benefit) provision (85,862 ) 875   (83,746 ) 1,532  
Net income $ 97,126   $ 4,869   $ 123,385   $ 26,762  
Net income per common share:
Basic $ 2.58   $ 0.13   $ 3.31   $ 0.84  
Diluted $ 2.47   $ 0.13   $ 3.17   $ 0.82  
Weighted-average common shares outstanding:
Basic 37,580   36,173   37,276   32,044  
Diluted 39,294   37,853   38,892   32,656  
 
 

Lantheus Holdings, Inc.

Consolidated Segment Revenues Analysis

(in thousands – unaudited)

 
  Three Months Ended
December 31,
  Year Ended
December 31,
2017   2016   % Change 2017   2016   % Change

United States

DEFINITY $ 40,546 $ 33,180 22.2 % $ 153,581 $ 128,677 19.4 %
TechneLite 21,339 21,130 1.0 % 90,489 85,412 5.9 %
Xenon 7,664 7,458 2.8 % 31,373 29,078 7.9 %
Other 1,747   2,965   (41.1 )% 14,559   14,253   2.1 %
Total United States 71,296   64,733   10.1 % 290,002   257,420   12.7 %

International

DEFINITY 1,153 932 23.7 % 3,687 2,935 25.6 %
TechneLite 3,405 3,466 (1.8 )% 14,155 13,805 2.5 %
Xenon 2 (100.0 )% 4 8 (50.0 )%
Other 5,387   5,217   3.3 % 23,530   27,685   (15.0 )%
Total International 9,945   9,617   3.4 % 41,376   44,433   (6.9 )%

Worldwide

DEFINITY 41,699 34,112 22.2 % 157,268 131,612 19.5 %
TechneLite 24,744 24,596 0.6 % 104,644 99,217 5.5 %
Xenon 7,664 7,460 2.7 % 31,377 29,086 7.9 %
Other 7,134   8,182   (12.8 )% 38,089   41,938   (9.2 )%
Total Revenues $ 81,241   $ 74,350   9.3 % $ 331,378   $ 301,853   9.8 %
 
 

Lantheus Holdings, Inc.

Supplemental Revenue Information

(unaudited)

 
  December 31, 2017
Quarter to Date Sales Growth/(Decline)

Domestic
As
Reported

 

Int’l
Constant
Currency

 

Int’l As
Reported

 

Total
Constant
Currency

 

Total As
Reported

Products
DEFINITY 22.2 % 20.0 % 23.7 % 22.1 % 22.2 %
TechneLite 1.0 % (5.7 )% (1.8 )% % 0.6 %
Xenon 2.8 % (100.0 )% (100.0 )% 2.7 % 2.7 %
Other (41.1 )% 2.8 % 3.3 % (13.1 )% (12.8 )%
Total Revenues 10.1 % 1.4 % 3.4 % 9.0 % 9.3 %
 
  December 31, 2017
Year to Date Sales Growth/(Decline)

Domestic
As
Reported

 

Int’l
Constant
Currency

 

Int’l As
Reported

 

Total
Constant
Currency

 

Total As
Reported

Products
DEFINITY 19.4 % 23.7 % 25.6 % 19.5 % 19.5 %
TechneLite 5.9 % 0.8 % 2.5 % 5.2 % 5.5 %
Xenon 7.9 % (50.0 )% (50.0 )% 7.9 % 7.9 %
Other 2.1 % (14.9 )% (15.0 )% (9.1 )% (9.2 )%
Total Revenues 12.7 % (7.5 )% (6.9 )% 9.7 % 9.8 %
 
 

Lantheus Holdings, Inc.

Reconciliation of Revenues to Revenues Excluding the Impact of Foreign Currency

(in thousands – unaudited)

 
  Three Months Ended
December 31, 2017
  Year Ended
December 31, 2017

International
Revenues

 

Total
Revenues

International
Revenues

 

Total
Revenues

Revenues $ 9,945 $ 81,241 $ 41,376 $ 331,378
Currency impact as compared to prior period (194 ) (194 ) (274 ) (274 )
Revenues, excluding the impact of foreign currency $ 9,751   $ 81,047   $ 41,102   $ 331,104  
 
 

Lantheus Holdings, Inc.

Reconciliation of GAAP to Non-GAAP Financial Measures

(in thousands – unaudited)

 
  Three Months Ended
December 31,
  Year Ended
December 31,
2017   2016 2017   2016
Operating income $ 9,207 $ 12,141 $ 51,853 $ 56,588
Campus consolidation costs including depreciation 731 1,181 6,510 1,181
Offering and other costs (26 ) 117 576 117
Non-recurring refinancing related fees 836 2,557
Loss (gain) on sales of assets 120 (6,385 )
One-time contract and termination costs 2,210 2,210
Loss on impairment of land 912     912    
Adjusted operating income $ 13,870   $ 13,559   $ 64,618   $ 51,501  
Adjusted operating income, as a percentage of revenues 17.1 % 18.2 % 19.5 % 17.1 %
 
 

Lantheus Holdings, Inc.

Reconciliation of GAAP to Non-GAAP Financial Measures

(in thousands, except per share data – unaudited)

 
 

Three Months Ended
December 31,

 

Year Ended
December 31,

2017   2016 2017   2016
Net income $ 97,126   $ 4,869   $ 123,385   $ 26,762  
Reconciling items impacting operating income:
Campus consolidation costs including depreciation 731 1,181 6,510 1,181
Offering and other costs (26 ) 117 576 117
Non-recurring refinancing related fees 836 2,557
Loss (gain) on sales of assets 120 (6,385 )
One-time contract and termination costs 2,210 2,210
Reconciling items impacting non-operating expenses and income taxes:
Loss on impairment of land 912 912
Loss on debt extinguishment and retirement costs 281 481 2,442 1,896
Income tax benefit for release of valuation allowance (141,094 ) (141,094 )
Impact of tax rate change on deferred taxes 45,129 45,129
Income tax effect of non-GAAP adjustments(a) (1,248 )   (3,840 )  
Adjusted net income $ 4,857   $ 6,768   $ 38,787   $ 23,571  
Adjusted net income, as a percentage of revenues 6.0 % 9.1 % 11.7 % 7.8 %
 
   

Three Months Ended
December 31,

Year Ended
December 31,

2017   2016 2017   2016
Net income per share - diluted $ 2.47   $ 0.13   $ 3.17   $ 0.82  
Reconciling items impacting operating income:
Campus consolidation costs including depreciation 0.02 0.04 0.17 0.04
Offering and other costs 0.01
Non-recurring refinancing related fees 0.02 0.07
Loss (gain) on sales of assets (0.20 )
One-time contract and termination costs 0.06 0.06
Reconciling items impacting non-operating expenses and income taxes:
Loss on impairment of land 0.02 0.02
Loss on debt extinguishment and retirement costs 0.01 0.01 0.06 0.06
Income tax benefit for release of valuation allowance (3.60 ) (3.62 )
Impact of tax rate change on deferred taxes 1.15 1.16
Tax effect of non-GAAP adjustments(a) (0.03 )   (0.10 )  
Adjusted net income per share - diluted $ 0.12   $ 0.18   $ 1.00   $ 0.72  
Weighted-average common shares outstanding - diluted 39,294   37,853   38,892   32,656  

(a) The income tax effect of the adjustments between GAAP net income and non-GAAP adjusted net income takes into account the tax treatment and related tax rate that apply to each adjustment in the applicable tax jurisdiction.

 

Lantheus Holdings, Inc.

Reconciliation of GAAP Reported to Non-GAAP Adjusted Information

Certain Line Items and Other Information

(in thousands, except per share data – unaudited)

 
  Three Months Ended
December 31, 2017   December 31, 2016
GAAP   Adjustments

Non-GAAP
Adjusted

GAAP   Adjustments

Non-GAAP
Adjusted

Cost of goods sold $ 43,342 $ (1,200 ) (a) $ 42,142 $ 39,703 $ $ 39,703
Gross profit $ 37,899 $ 1,200 $ 39,099 $ 34,647 $ $ 34,647
General and administrative $ 14,293 $ (3,463 ) (b) $ 10,830 $ 9,990 $ (117 ) (d) $ 9,873
Research and development $ 3,976 $ $ 3,976 $ 3,710 $ (1,181 ) (e) $ 2,529
Loss on sales of assets $ $ $ $ (120 ) $ 120 $
Operating income $ 9,207 $ 4,663 $ 13,870 $ 12,141 $ 1,418 $ 13,559
Debt retirement costs $ $ $ $ 481 $ (481 ) $
Loss on extinguishment of debt $ 281 $ (281 ) $ $ $ $
Income before income taxes $ 11,264 $ 4,944 $ 16,208 $ 5,744 $ 1,899 $ 7,643
Income tax (benefit) provision $ (85,862 ) $ 97,213 (c) $ 11,351 $ 875 $ $ 875
Net income $ 97,126 $ (92,269 ) $ 4,857 $ 4,869 $ 1,899 $ 6,768
Net income per common share - diluted $ 2.47 $ 0.12 $ 0.13 $ 0.18
 

(a) One-time contract and termination costs.

(b) Includes campus consolidation costs (including depreciation expense) of $0.7 million, one-time contract and termination costs of $1.0 million, non-recurring refinancing related fees of $0.8 million, loss on impairment of land of $0.9 million and offering and other costs.

(c) Includes the income tax effect of non-GAAP adjustments and the income tax benefit due to the release of our valuation allowance of $141.1 million against our deferred tax assets offset by a provision of $45.1 million for the remeasurement of our deferred tax assets for the change in tax rates enacted under the Tax Cuts and Jobs Act of 2017.

(d) Offering and other costs.

(e) Campus consolidation costs (including depreciation expense).

 

Lantheus Holdings, Inc.

Reconciliation of GAAP Reported to Non-GAAP Adjusted Information

Certain Line Items and Other Information

(in thousands, except per share data – unaudited)

 
  Twelve Months Ended
December 31, 2017   December 31, 2016
GAAP   Adjustments

Non-GAAP
Adjusted

GAAP   Adjustments

Non-GAAP
Adjusted

Cost of goods sold $ 169,243 $ (1,200 ) (a) $ 168,043 $ 164,073 $ $ 164,073
Gross profit $ 162,135 $ 1,200 $ 163,335 $ 137,780 $ $ 137,780
General and administrative $ 49,842 $ (11,565 ) (b) $ 38,277 $ 38,832 $ (117 ) (d) $ 38,715
Research and development $ 18,125 $ $ 18,125 $ 12,203 $ (1,181 ) (e) $ 11,022
Gain on sales of assets $ $ $ $ 6,385 $ (6,385 ) $
Operating income $ 51,853 $ 12,765 $ 64,618 $ 56,588 $ (5,087 ) $ 51,501
Debt retirement costs $ $ $ $ 1,896 $ (1,896 ) $
Loss on extinguishment of debt $ 2,442 $ (2,442 ) $ $ $ $
Income before income taxes $ 39,639 $ 15,207 $ 54,846 $ 28,294 $ (3,191 ) $ 25,103
Income tax (benefit) provision $ (83,746 ) $ 99,805 (c) $ 16,059 $ 1,532 $ $ 1,532
Net income $ 123,385 $ (84,598 ) $ 38,787 $ 26,762 $ (3,191 ) $ 23,571
Net income per common share - diluted $ 3.17 $ 1.00 $ 0.82 $ 0.72
 

(a) One-time contract and termination costs.

(b) Includes campus consolidation costs (including depreciation expense) of $6.5 million, non-recurring refinancing related fees of $2.6 million, one-time contract and termination costs of $1.0 million, loss on impairment of land of $0.9 million and offering and other costs of $0.6 million.

(c) Includes the income tax effect of non-GAAP adjustments and the income tax benefit due to the release of our valuation allowance of $141.1 million against our deferred tax assets offset by a provision of $45.1 million for the remeasurement of our deferred tax assets for the change in tax rates enacted under the Tax Cuts and Jobs Act of 2017.

(d) Offering and other costs.

(e) Campus consolidation costs (including depreciation expense).

 

Lantheus Holdings, Inc.

Reconciliation of GAAP to Non-GAAP Financial Measures

(in thousands – unaudited)

 
  Three Months Ended
December 31,
 

Year Ended
December 31,

2017   2016 2017   2016
Net income $ 97,126 $ 4,869 $ 123,385 $ 26,762
Interest expense, net 4,257 5,816 18,391 26,598
Income tax (benefit) provision(a) (92,759 ) 452 (92,113 ) 477
Depreciation 2,419 3,529 12,485 9,915
Amortization of intangible assets 1,794   2,070   6,747   8,348  
EBITDA 12,837 16,736 68,895 72,100
Stock and incentive plan compensation 2,034 791 6,769 3,527
Asset write-off (b) 1,246 818 3,430 1,906
Severance and recruiting costs (c) 682 204 1,715 2,090
Offering and other costs (d) (26 ) 117 576 126
Campus consolidation costs 51 1,152
Debt refinancing costs 836 2,557
Extinguishment of debt and debt retirement costs 281 481 2,442 1,896
Loss (gain) on sales of assets 120 (6,385 )
New manufacturer costs (e) 688 578 4,304 3,029
One-time contract and termination costs 2,210     2,210    
Adjusted EBITDA $ 20,839   $ 19,845   $ 94,050   $ 78,289  
Adjusted EBITDA, as a percentage of revenues 25.7 % 26.7 % 28.4 % 25.9 %
 

(a) Represents income tax (benefit) provision, less tax indemnification income associated with BMS. During the three and twelve months ended December 31, 2017, this amount includes the release of our valuation allowance against our deferred tax assets and changes enacted under the Tax Cuts and Jobs Act of 2017.

(b) Represents non-cash losses incurred associated with the write-down of land, inventory and other write-offs of long-lived assets. During the three and twelve months ended December 31, 2017, the amount includes an impairment of land of $0.9 million.

(c) The amounts consist of severance and recruitment costs related to employees, executives and directors.

(d) Represents offering costs incurred on behalf of certain shareholders pursuant to a registration rights agreement and other non-recurring costs.

(e) Represents internal and external costs associated with establishing new manufacturing sources for our commercial and clinical candidate products.

 

Lantheus Holdings, Inc.

Reconciliation of Free Cash Flow

(in thousands – unaudited)

 
  Three Months Ended
December 31,
  Year Ended
December 31,
2017   2016 2017   2016
Net cash provided by operating activities $ 13,086 $ 12,781 $ 54,777 $ 49,642
Capital expenditures (5,954 ) (2,422 ) (17,543 ) (7,398 )
Free cash flow $ 7,132   $ 10,359   $ 37,234   $ 42,244  
 
 

Lantheus Holdings, Inc.

Condensed Consolidated Balance Sheets

(in thousands – unaudited)

 
  December 31,
2017
  December 31,
2016
Assets
Current assets
Cash and cash equivalents $ 76,290 $ 51,178
Accounts receivable, net 40,259 36,818
Inventory 26,080 17,640
Other current assets 5,221   5,183  
Total current assets 147,850 110,819
Property, plant & equipment, net 92,999 94,187
Intangibles, net 11,798 15,118
Goodwill 15,714 15,714
Deferred tax assets, net 87,010 65
Other long-term assets 28,487   19,995  
Total assets $ 383,858   $ 255,898  
Liabilities and stockholders’ equity (deficit)
Current liabilities
Current portion of long-term debt $ 2,750 $ 3,650
Revolving line of credit
Accounts payable 17,464 18,940
Accrued expenses and other liabilities 26,536   21,249  
Total current liabilities 46,750 43,839
Asset retirement obligations 10,412 9,370
Long-term debt, net 265,393 274,460
Other long-term liabilities 38,012   34,745  
Total liabilities 360,567   362,414  
Total stockholders’ equity (deficit) 23,291   (106,516 )
Total liabilities and stockholders’ equity (deficit) $ 383,858   $ 255,898  

Source: Lantheus Holdings, Inc.

Lantheus Holdings, Inc.
Meara Murphy, 978-671-8508
Director, Investor Relations and Corporate Communications